The 68Ga PSMA PET/CT (or PET/MR) hybrid modality may provide localization staging of primary prostate cancer, guide biopsy, and even offer future opportunities for focal therapy through theranostics. The gene discussed is FOLH1; the disease is prostate carcinoma.